BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Berberine ursodeoxycholate (HTD1801) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Berberine ursodeoxycholate (HTD1801)\, fr
 om ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07496177-455@assetmemo.bio
DTSTAMP:20261121T004107Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Berberine ursodeoxycholate (HTD1801): Phase 2 readout est. (NCT0749
 6177)
DESCRIPTION:Berberine ursodeoxycholate (HTD1801)\, phase 2\, Type 2 Diabete
 s.\nStudy: A Mechanistic Study on the Effect of HTD1801 Versus Placebo on 
 Kidney Function in Patients With Type 2 Diabetes and Chronic Kidney Diseas
 e.\nEstimated primary completion: 31 May 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/berberine-ursodeoxycholate-htd1801#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07496177
URL:https://assetmemo.bio/drug/berberine-ursodeoxycholate-htd1801#upcoming-
 events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
